◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › A › ARGX

argenx NV ADR (ARGX) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-10

argenx NV ADR (ARGX) operates in the BIOTECHNOLOGY industry and is headquartered in Amsterdam, Netherlands with about 1,863 employees. Its market capitalization is roughly $62 billion. In the fiscal year ended 2025-12-31, ARGX reported $4.2B in revenue and $1.3B in net income.

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.

Interactive charts & full statements → Open the ARGX valuation workbench →

ARGX Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Total Revenue	$8.4B	$4.2B	$2.2B	$1.2B	$411M	$1.1B	$41M	$78M	$25M	$44M	$15M	$7M	$5M	$4M	$2M	$1M
Gross Profit	$7.6B	$3.7B	$2.0B	$1.1B	$381M	$497M	$41M	$78M	$25M	$44M	$15M	$7M	$5M	$3M	$2M	$1M
Gross Margin %	89.9%	89.1%	89.6%	90.4%	92.8%	46.1%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	72.4%	100.0%	100.0%
Operating Income (EBIT)	$2.4B	$1.1B	($22M)	($425M)	($720M)	($349M)	($478M)	($199M)	($94M)	($28M)	($23M)	($17M)	($13M)	($9M)	($13M)	($5M)
Operating Margin %	28.9%	25.4%	-1.0%	-34.7%	-175.4%	-32.4%	-1158.1%	-253.5%	-381.0%	-63.0%	-145.6%	-227.7%	-286.1%	-238.2%	-608.9%	-323.6%
Net Income	$2.6B	$1.3B	$833M	($295M)	($710M)	($408M)	($608M)	($181M)	($76M)	($34M)	($22M)	($17M)	($13M)	($8M)	($13M)	($4M)
Net Margin %	30.7%	31.1%	38.0%	-24.1%	-172.8%	-37.9%	-1475.3%	-230.9%	-310.2%	-77.1%	-145.3%	-223.4%	-274.6%	-229.0%	-587.5%	-308.0%
EBITDA	—	$1.3B	$105M	($192M)	($623M)	($393M)	($601M)	($173M)	($93M)	($32M)	($22M)	($17M)	($12M)	($8M)	($13M)	($4M)
Earnings Per Share (EPS)	—	$19.57	$12.78	$-5.16	$-13.05	$-7.99	$-13.40	$-4.69	$-2.12	$-1.37	$-1.19	$-1.06	$-0.80	$-0.54	$-0.82	$-0.29
Shares Outstanding (M)	64M	66M	65M	57M	54M	51M	45M	39M	36M	25M	19M	16M	16M	16M	16M	16M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ARGX Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$2.8B	$1.3B	$3.2B	$1.1B	$948M	$791M	$1.3B	$573M
Gross Profit	$2.5B	$1.2B	$2.9B	$1.0B	$837M	$710M	$681M	$514M
Gross Margin %	90.1%	90.7%	89.4%	90.3%	88.3%	89.8%	50.6%	89.7%
Operating Income (EBIT)	$847M	$394M	$851M	$350M	$204M	$141M	$117M	$14M
Operating Margin %	30.1%	30.3%	26.5%	31.1%	21.5%	17.9%	8.7%	2.5%
Net Income	$839M	$366M	$1.0B	$344M	$245M	$169M	$866M	$91M
Net Margin %	29.8%	28.2%	32.6%	30.6%	25.9%	21.4%	64.3%	16.0%
EBITDA	$864M	—	$1.0B	—	$288M	$203M	$127M	$89M
Earnings Per Share (EPS)	$13.02	—	$15.81	—	$3.74	$2.58	$12.20	$1.39
Shares Outstanding (M)	64M	—	66M	—	66M	66M	71M	66M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ARGX Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Cash from Operations (CFO)	—	$850M	($83M)	($420M)	($863M)	($607M)	($398M)	$152M	($62M)	($44M)	$11M	($15M)	($6M)	($9M)	($11M)	($4M)
Capital Expenditures (CapEx)	$4M	$6M	$68M	$44M	$104M	$121M	$5M	$47M	$1M	$0M	$1M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	—	$844M	($151M)	($464M)	($967M)	($728M)	($404M)	$105M	($62M)	($44M)	$10M	($15M)	($7M)	($9M)	($11M)	($4M)
FCF Margin %	—	20.3%	-6.9%	-37.9%	-235.3%	-67.6%	-978.6%	133.7%	-253.8%	-101.3%	66.2%	-206.8%	-144.3%	-249.2%	-513.1%	-294.4%
Dividends Paid	—	—	—	—	$5M	—	—	$0M	$0M	$0M	$0M	$0M	$0M	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ARGX Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2025-12-31	2025-06-30	2024-12-31
Cash from Operations (CFO)	$752M	$408M	$438M	$42M
Capital Expenditures (CapEx)	$3M	$1M	$5M	$1M
Free Cash Flow (FCF)	$749M	$407M	$433M	$41M
FCF Margin %	26.6%	12.7%	45.6%	3.0%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ARGX Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31
Total Assets	$10.0B	$8.7B	$6.2B	$4.5B	$3.1B	$2.9B	$2.3B	$1.6B	$662M	$445M	$111M	$50M	$59M	$35M	$23M	$32M	$12M
Cash & Cash Equivalents	$3.6B	$3.5B	$1.5B	$2.0B	$801M	$1.3B	$1.2B	$372M	$321M	$229M	$95M	$39M	$39M	$31M	$20M	$31M	$11M
Total Liabilities	$1.6B	$1.4B	$704M	$445M	$321M	$316M	$605M	$430M	$46M	$31M	$45M	$9M	$8M	$5M	$6M	$4M	$2M
Total Debt (Short + Long-Term)	$11M	$11M	$7M	$5M	$3M	$4M	$3M	$2M	$0M	$0M	$0M	$0M	$0M	$0M	$2M	$2M	$0M
Total Shareholders' Equity	$8.4B	$7.3B	$5.5B	$4.1B	$2.8B	$2.5B	$1.7B	$1.2B	$616M	$414M	$67M	$41M	$61M	$30M	$17M	$28M	$10M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ARGX viewer.

Other Companies in BIOTECHNOLOGY

RVMD · Revolution Medicines Inc — $41 billion
ONC · BeiGene, Ltd. — $40 billion
RPRX · Royalty Pharma Plc — $34 billion
ALNY · Alnylam Pharmaceuticals Inc — $32 billion
ROIV · Roivant Sciences Ltd — $29 billion
INSM · Insmed Inc — $26 billion
BNTX · BioNTech SE — $24 billion
GMAB · Genmab AS — $21 billion

← ARGT All “A” companies ARHS →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.